Aguila PG, García VA, Martínez TL, Lores VL, Fernández CM, Pérez MS, Martínez BMV

Language: Spanish
References: 19
Page: 1-19
PDF size: 312.22 Kb.

ABSTRACT

Introduction: Among the medicines of aica+ Laboratories Company are the lyophilized injectables vancomycin 500 mg and omeprazole 40 mg, whose prescriptions were modified according to the new conditions of the entity.
Objective: To evaluate the homogeneity of the drying of omeprazole and vancomycin injectables.
Methods: For the study of homogeneity of drying, bulbs were sampled from all the plates, through the evaluation of the distribution of the data. Samples were selected from each of the industrial batches of both injectables, and the residual moisture content was determined by statistical processing to determine the existence or not of significant differences at the plate level and between batches.
Quality controls were performed on all batches, including organoleptic characteristics, pH, titration, sterility and endotoxins. Results: The values of residual moisture content of both injectables complied with the normal distribution and with the established limits. It was found that there were no significant differences between the residual moisture values of the bulbs placed on the same plate and between different plates, but not between batches, thus the drying process was considered homogeneous for the products of interest. The industrial batches, freshly processed, satisfactorily met the quality specifications established for both products.
Conclusions: The freeze-drying process performed for omeprazole and vancomycin injectables proved to be homogeneous for the conditions existing in the producing entity, under the conditions existing in the producing entity.

REFERENCES

1. Izutsu K. Applications of Freezing and Freeze-Drying in Pharmaceutical Formulations. In: Iwaya-Inoue M, Sakurai M, Uemura M, editors. Survival Strategies in Extreme Cold and Desiccation. Advances in Experimental Medicine and Biology. Singapore: Springer; 2018.pp. 371-83. DOI: 10.1007/978-981-13-1244-1_20

2. Kawasaki H, Shimanouchi T, Kimura Y. Recent Development of Optimization of Lyophilization Process. Journal of Chemistry. 2019;9502856. DOI: 10.1155/2019/9502856

3. Seifert I, Friess W. Freeze concentration during freezing: How does the maximally freeze concentrated solution influence protein stability? Int J Pharm. 2020;589:119810. DOI: 10.1016/j.ijpharm.2020.119810

4. Nail SL, Jiang S, Chongprasert S, Knopp SA. Fundamentals of freeze-drying. Pharm Biotechnol. 2002;14:281-60. DOI: 10.1007/978-1-4615-0549-56

5. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int JPharm. 2000;203:1-60. DOI: 1.116/s378-5173(00)00423-3

6. Goldman JM, More HT, Yee O, Borgeson E, Remy B, Rowe J, et al. Optimization of Primary Drying in Lyophilization During Early-Phase Drug Development Using a Definitive Screening Design With Formulation and Process Factors. J PharmSci. 2018;1-9. DOI: 10.1016/j.xphs.2018.06.001

7. Tang C, Pikal M. Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice. AAPS Pharm SciTech. 2004;21(2):191-00. Disponible en: 10.1023/B: PHAM.0000016234.73023.75

8. Shirkole S, Thorat N, Mujumdar A. Critical reviews for facilitating innovations and advances in drying science and technology. Drying Technology. 2021;39(5):577-79. DOI: 10.1080/07373937.2021.1880178

9. Pérez M, López E, Fernández M, Cabrera L, Acosta M, Tusell Y. Homogeneidad del secado de los inyectables liofilizados ácido zoledrónico y omeprazol. Rev Mex Cienc Farm. 2016 [acceso10/11/2021];47(4):79-85. Disponible en: http://www.redalyc.org/articulo.oa?id=57956612007

10. Navarro M. La Liofilización de Productos Farmacéuticos. La Habana, SINTEFARMA. 1998 [acceso10/11/2021];4(1). Disponible en: http://pesquisa.bvsalud.org/portal/resource/es/cum-16383

11. Patel SM, Nail SI, Pikal MJ, Geidobler R, Winter G, Hawe A, et al. Lyophilized Drug Product Cake Appearance: What Is Acceptable? J Pharm Sci. 2017;106:1706-21. DOI: 10.1016/j.xphs.2017.03.014

12. Fonte P, Reis S, Sarmento B. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. Journal of Controlled Release. 2016;225:75-86. DOI: 10.1016/j.jconrel.2016.01.034

13. Affleck R, Khamar D, Lowerre KM, Adler N, Cullen S, Yang M, McCoy T. Near Infrared and Frequency Modulated Spectroscopy as Non-Invasive Methods for Moisture Assessment of Freeze-Dried Biologics. J Pharm Sci. 2021;110:3395-3402. DOI: 10.1016/j.xphs.2021.06.016

14. Thomson A, Sauve M, Kassam N, Kamitakahara H. Inhibidores de la bomba de protones. Safety of the long-term use of proton pump inhibitors. Gastroenterology. 2010;16 (19):2323. DOI: 10.3748/wjg.v16.i19.2323

15. Xie C, Liu L, Zhu S, Wei M. Effectiveness and safety of Chinese medicine combined with omeprazole in treatment of gastric ulcer: A protocol for systematic review and meta-analysis. Medicine. 2021;100:17. DOI: 10.1097/MD.0000000000025744

16. Brunton L, Hilah-Dandan R, Knollmann BC, Editors. Goodman and Gilman: The Pharmacological Basis of Therapeutics. 13th Edition. New York (USA): McGraw-Hill; 2017 [acceso 10/11/2021], p.1440. Disponible en: https://accessmedicine.mhmedical.com/book.aspx?bookID=2189#165936881

17. Nakano T, Kawahira T, Kaneshige S, Hayashi T, Kamikura H, Mizuno Y, et al. Influence of Empirical Therapy Utilizing Vancomycin in Patients with Suspected Bacterial Meningitis: A Single-Center Retrospective Study; 2020. DOI: 10.1248/bpbreports.3.5_150

18. United States Pharmacopeia 42 Ed. (USP 42). United States Pharmacopoeia. US Pharmacopoeia Convention. Rockville: Mack Printing; 2019 [acceso 12/01/2022]. Disponible en: https://www.uspnf.com

19. AstraZeneca AB. Dossier del fabricante. Omeprazol, inyectable liofilizado (40 mg) Suecia: AstraZeneca Pharmaceutical Company; 2003 [acceso 12/02/2022]. Disponible en: https://patents.google.com/patent/US6143771A/en